MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Lung Cancer

Chimeric antigen receptor (CAR) T-cell therapy for thoracic malignancies

Journal of Thoracic Oncology 2017 October [Epub ahead of print] [Link] Kiesgen S, Chicaybam L, Chintala NK, Adusumilli PS Abstract Chimeric antigen receptor (CAR) T cells are patient T cells that are transduced with genetically engineered synthetic receptors to target a cancer cell surface antigen. The remarkable clinical response rates achieved by adoptive transfer of […]

Comments Off on Chimeric antigen receptor (CAR) T-cell therapy for thoracic malignancies

Multicentric initial experience with the use of the pressurized intraperitoneal aerosol chemotherapy (PIPAC) in the management of unresectable peritoneal carcinomatosis

European Journal of Surgical Oncology 2017 September [Epub ahead of print] [Link] Alyami M, Gagniere J, Sgarbura O, Cabelguenne D, Villeneuve L, Pezet D, Quenet F, Glehen O, Bakrin N, Passot G Abstract BACKGROUND: PIPAC is a recent approach for intraperitoneal chemotherapy with promising results for patients with peritoneal carcinomatosis (PC). We aimed to evaluate […]

Comments Off on Multicentric initial experience with the use of the pressurized intraperitoneal aerosol chemotherapy (PIPAC) in the management of unresectable peritoneal carcinomatosis

The PD-L1/PD-1 pathway promotes dysfunction, but not “exhaustion”, in tumor-responding T cells from pleural effusions in lung cancer patients

Cancer Immunology, immunotherapy [Epub 2017 March 13] [Link] Prado-Garcia H, Romero-Garcia S, Puerto-Aquino A, Rumbo-Nava U Abstract Malignant pleural effusions are frequent in patients with advanced stages of lung cancer and are commonly infiltrated by lymphocytes and tumor cells. CD8+ T cells from these effusions have reduced effector functions. The programmed death receptor 1(PD-1)/programmed death […]

Comments Off on The PD-L1/PD-1 pathway promotes dysfunction, but not “exhaustion”, in tumor-responding T cells from pleural effusions in lung cancer patients

Italian pool of asbestos workers cohorts: mortality trends of asbestos-related neoplasms after long time since first exposure

Occupational and Environmental Medicine 2017 August [Epub ahead of print] [Link] Ferrante D, et.al. Abstract OBJECTIVE: Asbestos is a known human carcinogen, with evidence for malignant mesothelioma (MM), cancers of lung, ovary, larynx and possibly other organs. MM rates are predicted to increase with a power of time since first exposure (TSFE), but the possible […]

Comments Off on Italian pool of asbestos workers cohorts: mortality trends of asbestos-related neoplasms after long time since first exposure

Diagnostic value of medical thoracoscopy in malignant pleural effusion

BMC Pulmonary Medicine 2017 August [Link] Wu YB, Xu LL, Wang XJ, Wang Z, Zhang J, Tong ZH, Shi HZ Abstract BACKGROUND: Medical thoracoscopy has been shown to be an efficacious procedure in diagnosing unexplained exudative pleural effusions with excellent safety. This study aimed to assess the diagnostic significance of thoracoscopy in the management of […]

Comments Off on Diagnostic value of medical thoracoscopy in malignant pleural effusion

Lung cancer in a patient with predominantly short tremolite fibers in his lung

American Journal of Industrial Medicine 2017 July [Epub ahead of print] [Link] Kohyama N, Fujiki M, Kishimoto T, Morinaga K Abstract The carcinogenicity of short tremolite fibers in human has not been cleared and has been argued hitherto. A lung cancer patient had worked at a gabbro quarry. Particles isolated from the excised lung parenchyma […]

Comments Off on Lung cancer in a patient with predominantly short tremolite fibers in his lung

Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial

The Lancet.Oncology 2017 July 17 [Epub ahead of print] [Link] Maio M, Scherpereel A, CalabrĂ² L, Aerts J, Perez SC, Bearz A, Nackaerts K, Fennell DA, Kowalski D, Tsao AS, Taylor P, Grosso F, Antonia SJ, Nowak AK, Taboada M, Puglisi M, Stockman PK, Kindler HL Abstract BACKGROUND: New therapeutic strategies for malignant mesothelioma are […]

Comments Off on Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial

Viroimmunotherapy of Thoracic Cancers

Biomedicines 2017 January [Link] Dash AS, Patel MR Abstract Thoracic cancers, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and malignant pleural mesothelioma (MM), cause the highest rate of cancer mortality worldwide. Most of these deaths are as a result of NSCLC; however, prognoses for the other two diseases remain as some […]

Comments Off on Viroimmunotherapy of Thoracic Cancers

CAR T-cell therapy for lung cancer and malignant pleural mesothelioma

Translational Research [Epub ahead of print] [Link] Zeltsman M, Dozier J, McGee E, Ngai D, Adusumilli PS Abstract Immunotherapy is a promising field that harnesses the power of the immune system as a therapeutic agent for cancer treatment. Beneficial outcomes shown in patients with non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma (MPM) with […]

Comments Off on CAR T-cell therapy for lung cancer and malignant pleural mesothelioma

Successful lung-sparing resection of synchronous pleural mesothelioma and contralateral lung cancer

Surgical Case Reports [Epub May 8] [Link] Imanishi N, Nabe Y, Takenaka M, Chikaishi Y, Kuroda K, Noguchi 2, Yatera K, Tanaka F Abstract BACKGROUND: Malignant pleural mesothelioma (MPM) is an uncommon malignant tumor, and its synchronous occurrence with primary lung cancer is extremely rare. Here, we report the first surgical case of synchronous MPM […]

Comments Off on Successful lung-sparing resection of synchronous pleural mesothelioma and contralateral lung cancer